Drug profile · INN
saralasin acetate
SARENIN
saralasin acetate (SARENIN) is a type-1 angiotensin ii receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — saralasin acetate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
saralasin acetate (SARENIN) is a type-1 angiotensin ii receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is saralasin acetate?
saralasin acetate (SARENIN) is a type-1 angiotensin ii receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for saralasin acetate?
SARENIN is a marketed brand name for saralasin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of saralasin acetate?
saralasin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.